[{"orgOrder":0,"company":"AI Proteins","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Miniprotein-Based Therapeutics","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"AI Proteins","amount2":0.40000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.40000000000000002,"dosageForm":"","sponsorNew":"AI Proteins \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"AI Proteins \/ Bristol Myers Squibb"}]

Find Clinical Drug Pipeline Developments & Deals by AI Proteins

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Under the collaboration, AI Proteins will leverage its proprietary AI-driven platform to design and optimize novel miniprotein-based therapeutics against targets of interest to Bristol Myers Squibb.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 03, 2024

                          Lead Product(s) : Miniprotein-Based Therapeutics

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery Platform

                          Sponsor : Bristol Myers Squibb

                          Deal Size : $400.0 million

                          Deal Type : Collaboration

                          blank